Hyperkalemia

More than 2% of the U.S. Medicare population has hyperkalemia, with a higher prevalence among adults with chronic kidney disease or heart failure, according to a study published in Current Medical Research and Opinion.

The FDA has updated the dosing regimen for Lokelma to allow treatment of hyperkalemia in patients with end-stage kidney disease who are on chronic hemodialysis.

Despite guidelines recommending chlorthalidone over hydrochlorothiazide for hypertension, the drugs have similar effectiveness and chlorthalidone was associated with a significantly worse safety profile, according to research published in JAMA Internal Medicine.

WASHINGTON — Patiromer was effective in controlling serum potassium in hyperkalemic patients with diabetes and advanced kidney disease on renin-angiotensin-aldosterone system inhibitors, according to research presented here.

WASHINGTON — Study results presented at ASN Kidney Week described the characteristics of patients who were more likely to be treated with insulin for hyperkalemia, a treatment which researchers argued is associated with longer hospital stays and increased mortality risk.

The National Dialysis Accreditation Commission was the first dialysis accreditation organization in the United States to receive approval from CMS for deeming authority for ESRD Medicare Certification. Approved in January 2019, the National Dialysis Accreditation Commission is the only accreditation organization in the United States formed by dialysis experts and focuses exclusively on serving the dialysis community.

PHILADELPHIA — Concomitant use of the potassium binder patiromer enabled more patients with resistant hypertension and advanced chronic kidney disease to continue treatment with spironolactone, with less hyperkalemia, according to new data from the AMBER trial presented at the Heart Failure Society of America Scientific Meeting.

The American Kidney Fund has launched a new health education campaign for patients with kidney disease, according to a press release. The campaign, entitled Beyond Bananas, is designed to bolster patient-knowledge of hyperkalemia, thereby better enabling potassium control.

As students go back to school and parents resign beach gear to its out-of-season digs at the back of the garage, Healio Dermatology reflects on big news from August on acne treatment, private equity in the marketplace and much more.

PARIS — Sacubitril/valsartan did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved ejection fraction, defined as at least 45%, according to a hot line trial presented at the European Society of Cardiology Congress.